27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a note released Wednesday, Citi analyst Jonathan Eckard says the drop in Intercept Pharmaceuticals (NASDAQ: ICPT) shares over the past couple months, due to negative emails between Intercept's Chief Medical Officer and an officer at the National Institute of Health were "overdone."
Eckard believes the current price reflects low expectations for July data regarding nonalcoholic steatohepatitis or NASH.
The Citi analyst reduced his price target on shares of Intercept from $700 to $693 and maintained a Buy rating.
Shares of Intercept are down slightly (0.8 percent) in Wednesday's session at $239.74.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!